CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

August 1, 2026 · Phase 3 readout

BMRN Phase 3 readout: a neutral outcome, -2.2%

On August 1, 2026, Vosoritide — BioMarin Pharmaceutical Inc. (Hypochondroplasia) reached its Phase 3 readout. The result was a neutral outcome, and the stock moved -2.2% in the window around the event.

The move

$54.09
1d before
$52.88
Event day
$52.38
1d after
$57.29
5d after

Pre-catalyst setup

+1.7%
30-day run-up
4140%
30-day volatility
1.2×
volume spike